Loading
institutionsInstitution
Postgraduate Institute of Medical Education and Research, Chandigarh
PGIMER Chandigarh is the main tertiary referral hospital for north-west India and the regional cancer centre for Punjab and Haryana; its nuclear medicine department is among India's most active in PSMA and FAPI PET imaging and lutetium radioligand therapy.
Also called: PGIMERPGI Chandigarh
Overview
PGIMER was established in 1962 and is the main tertiary referral centre for north-west India. Its oncology services span a regional cancer centre with radiotherapy and brachytherapy, medical and surgical oncology, and paediatric haematology-oncology, and its Department of Nuclear Medicine is among India's most active in PSMA and FAPI PET imaging and lutetium-based radioligand therapy. PGIMER researchers publish extensively on cervical cancer screening, gallbladder cancer, chronic myeloid leukaemia and cancer epidemiology in Punjab, and the institute leads the population cancer registries for the region and Indian cooperative trials.
Location
Chandigarh, IN
Type
hospital
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#239 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Post Graduate Institute of Medical Education and Research, including child institutions. 398 works · 3,509 citations · 59% open access · 4% clinical trials · 3% reviews.
Oncology works per year
972022
762023
832024
822025
602026
Most works
- Bhagwant Rai Mittal24 works
- Pankaj Malhotra24 works
- Amanjit Bal20 works
- Surinder Singh Rana18 works
- Harmandeep Singh16 works
- Rajender Kumar16 works
- Navneet Singh15 works
- Harjeet Singh15 works
- Jaya Shukla14 works
- Sharat Damodar14 works
Most cited
- Nuclear medicine and theranostics
- Radiotherapy and brachytherapy
- Haematology
- Cancer registry
Similar pages
- PersonKen Herrmann
Shares FAPI PET, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares FAPI PET, Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares FAPI PET, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PairingBeta radioligand → alpha radioligand
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, Radioligand therapy (beta emitters), Neuroendocrine tumours.
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- InstitutionAll India Institute of Medical Sciences, New Delhi
Shares FAPI PET, PSMA PET, Radioligand therapy (beta emitters), Biliary tract cancer (cholangiocarcinoma).
- PersonLouise Emmett
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
cancers
fronts
technologies
drugs
ApprovedRadioligand therapy (beta)
Lutetium-177 dotatate · Lutathera
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto